GHK-Cu
Copper peptide GHK-Cu · Copper tripeptide-1 · GHK-copper · Glycyl-L-histidyl-L-lysine copper · Copper peptide · Prezatide copper
Snapshot
| Indications | Contraindications |
|---|---|
|
Glycyl-L-histidyl-L-lysine (GHK) copper, written GHK-Cu, is a copper(II) complex of a naturally occurring tripeptide, studied for matrix remodeling, inflammation, redox regulation, and tissue repair7. The United States (US) Food and Drug Administration (FDA) lists GHK-Cu, except for injectable routes, among bulk drug substances under evaluation for pharmacy compounding6. People use it topically for skin aging and barrier support, for skin quality after laser resurfacing, and for scalp and hair concerns.
Human research is limited to about three small trials, covering diabetic foot ulcers, laser-resurfaced skin, and scalp hair. A randomized trial after laser resurfacing found no objective difference in erythema or wrinkles, though patient-rated skin quality favored GHK-Cu2. A 2018 open-label pilot of scalp injections reported reduced hair fall, but the formulation combined several growth factors with copper tripeptide-13. A 2026 evidence-mapping review judged the clinical evidence sparse and GHK-Cu promising but unproven, with a phase 2 acute-wound trial still recruiting7. Products are mostly cosmetic serums, creams, and gels, often paired with other actives; see Form comparison1, 4.
Last updated October 17, 2026. Read how we make monographs.
In the full monograph
21 sources, 9 studies
- When to useThe situations practitioners use it for, each with the reason and the study behind it.
- SafetyWho should avoid it, who needs extra care, and the side effects reported in studies.
- Protocol notesThe doses used in studies, how and when they were taken, and how the forms on the market compare.
- How it worksWhat it is and how it works in the body, in plain terms.
- Published studiesThe studies behind each use, popular claims checked against them, and trials still under way.
- Word of mouthWhat patients and practitioners report online, kept separate from the clinical evidence.
- Clinical perspectiveA closing read of where the evidence is solid, where it is thin, and what has not been studied.
Sources
- 1Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.pubmed.ncbi.nlm.nih.govWang, Tao, Huang et al. · Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026 · Pubmed
- 2Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.pubmed.ncbi.nlm.nih.govMiller, Wagner, Baack et al. · Archives of facial plastic surgery · 2006 · Pubmed
- 3Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.pubmed.ncbi.nlm.nih.govKapoor, Shome · Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018 · Pubmed
- 4An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.pubmed.ncbi.nlm.nih.govPatel, Patel, Merja et al. · Cureus · 2024 · Pubmed
- 5Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.pubmed.ncbi.nlm.nih.govPatel, Patel, Merja et al. · Cureus · 2025 · Pubmed
- 6US statusfda.govWhat the FDA (its lists of substances nominated for pharmacy compounding, and Drugs@FDA) and the World Anti-Doping Agency's Prohibited List say about this ingredient, in their own words. A legal status, not evidence of benefit or harm
- 7GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap.pubmed.ncbi.nlm.nih.govMateescu, Gavrilescu, Mincioaga et al. · Pharmaceutics · 2026 · Pubmed